US FDA declines to approve Outlook Therapeutics' drug for eye condition-March 2024-www.financetom.com

US FDA declines to approve Outlook Therapeutics' drug for eye condition

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Aug 28, 2025 3:58 AM

Aug 28 (Reuters) - The U.S. Food and Drug Administration

has declined to approve Outlook Therapeutics' ( OTLK )

experimental drug to treat a type of eye condition that causes

blurred vision, the company said on Thursday.

Previous page： Sector Update: Consumer Next page： GSK Buys Elsie Biotechnologies for $50 Million

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Sector Update: Consumer

Jun 6, 2024

08:44 AM EDT, 06/06/2024 (MT Newswires) -- Consumer stocks were leaning lower pre-bell Thursday as the Consumer Staples Select Sector SPDR Fund (XLP) was down 0.1% and the Consumer Discretionary Select Sector SPDR Fund (XLY) was marginally declining recently. Five Below ( FIVE ) declined by over 18% as its fiscal Q1 sales and earnings lagged market expectations and the...

GSK Buys Elsie Biotechnologies for $50 Million

Jun 6, 2024

08:41 AM EDT, 06/06/2024 (MT Newswires) -- GSK (GSK) said Thursday it has completed its acquisition Elsie Biotechnologies for up to $50 million. The acquisition will enhance GSK's research and development capabilities with Elsie's portfolio in oligonucleotide therapeutics, an alternative to traditional biologics. Price: 42.05, Change: +0.08, Percent Change: +0.19 ...

Bitdeer Technologies Group Agrees to Acquire Desiweminer in All-Stock Deal

Jun 6, 2024

08:43 AM EDT, 06/06/2024 (MT Newswires) -- Bitdeer Technologies Group ( BTDR ) said Thursday that it has agreed to acquire all issued and outstanding shares of Desiweminer for 20 million Class A ordinary shares. Bitdeer ( BTDR ) said a portion of the shares to be issued will vest in equal installments over five or seven years. Additionally, Bitdeer...

Core Scientific Rejects CoreWeave's Acquisition Offer

Jun 6, 2024

08:44 AM EDT, 06/06/2024 (MT Newswires) -- Core Scientific ( CORZ ) said on Thursday it had rejected CoreWeave's proposal to buy all of its outstanding shares for $5.75 per share in cash, as it significantly undervalues the company and is not in the best interests of the shareholders. The company said it received the unsolicited proposal from CoreWeave on...